Nevertheless, treatment options with TKIs and ALK inhibitors are limited to a minority of patients, harboring targetable EGFR or ALK mutations in their tumor cells, and rates of acquired therapy resistance remain very high in clinical settings (Rolfo et al., 2014). This evidence concerns the gene ALK and neoplasm.